NCT05933863Completed
Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance
Source: ClinicalTrials.gov · Last updated 16 Dec 2024
Brief summary (registry, in English)
To validate the predictive value of transcriptome-based molecular subtyping of extensive stage small cell lung cancer (SCLC) for the efficacy of programmed death-1(PD-1)/programmed death-ligand1(PD-L1) inhibitor in the first line setting; to explore the differences of immune microenvironment between different SCLC subtypes to reveal the mechanisms of immunotherapy resistance of SCLC
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 168 (actual)
- First submitted
- 24 Jun 2023
- Start date
- Mar 2022
- Primary completion date
- Jul 2024
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Lung cancer
- NCT number
- NCT05933863
What you commit to
- Study type: Observational
- Participants enrolled: 168
- From Mar 2022 to the primary completion date, Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Those meeting any of the following conditions may not be included.
- Patient unable to tolerate chemotherapy.
- Patients unable to provide tumor tissue samples for testing
- Patients with other malignant tumors or a history of other malignant tumors
- Patients have any other reason to be unfit to participate in this study.
Who the study is looking for
- The enrolled subjects shall meet all the following conditions at the same time.
- Male or female, aged 18 to 100 years
- Patients with untreated advanced small cell lung cancer clearly diagnosed by histopathology
- Be able to provide tumor biopsy tissue sample for molecular analysis
- Eastern Cooperative oncology Group (ECOG) score: 0\~2
- Expected survival of more than 3 months.
- Has at least 1 measurable or evaluable tumor lesion with a longest diameter ≥ 10 mm at baseline (in case of lymph nodes, a shortest diameter ≥ 15 mm is required) according to RECIST v1.1
- Received first-line chemotherapy or chemotherapy＋PD-(L)1 inhibitor and be able to provide complete treatment information and efficacy evaluation results.
- Voluntary signed informed consent and expected good compliance.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Cancer Hospital & Institute Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.